Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses.
Kelly RJ, Landon BV, Zaidi AH, Singh D, Canzoniero JV, Balan A, Hales RK, Voong KR, Battafarano RJ, Jobe BA, Yang SC, Broderick S, Ha J, Marrone KA, Pereira G, Rao N, Borole A, Karaindrou K, Belcaid Z, White JR, Ke S, Amjad AI, Weksler B, Shin EJ, Thompson E, Smith KN, Pardoll DM, Hu C, Feliciano JL, Anagnostou V, Lam VK. Kelly RJ, et al. Among authors: karaindrou k. Nat Med. 2024 Apr;30(4):1023-1034. doi: 10.1038/s41591-024-02877-z. Epub 2024 Mar 19. Nat Med. 2024. PMID: 38504015 Free PMC article. Clinical Trial.
Druggable genomic landscapes of high-grade gliomas.
Ghanem P, Fatteh M, Kamson DO, Balan A, Chang M, Tao J, Blakeley J; Johns Hopkins Molecular Tumor Board Investigators; Canzoniero J, Grossman SA, Marrone K, Schreck KC, Anagnostou V. Ghanem P, et al. Front Med (Lausanne). 2023 Dec 8;10:1254955. doi: 10.3389/fmed.2023.1254955. eCollection 2023. Front Med (Lausanne). 2023. PMID: 38143440 Free PMC article.
Poly (ADP-ribose) Polymerase Inhibitor Resistance Driven by Emergence of Polyclonal Mutations With Convergent Evolution: A Molecular Tumor Board Discussion.
Fatteh M, Wehr J, Karaindrou K, Xian RR, Gocke C, Lin MT, Petry D, Visvanathan K, Couzi R, Santa Maria C, Stearns V, Tao JJ, Anagnostou V, Canzoniero JV; and the Johns Hopkins Molecular Tumor Board; Johns Hopkins Molecular Tumor Board. Fatteh M, et al. Among authors: karaindrou k. JCO Precis Oncol. 2024 Oct;8:e2400254. doi: 10.1200/PO.24.00254. Epub 2024 Oct 11. JCO Precis Oncol. 2024. PMID: 39393037 Free PMC article.